| <strong>bDMARDs</strong>: TNF inhibitors (etanercept, adalimumab, certolizumab, golimumab, infliximab), IL-6R inhibitors (tocilizumab, sarilumab), IL-17 inhibitors (secukinumab, ixekizumab), IL-12/23 inhibitors (ustekinumab), IL-23 inhibitors (guselkumab, tildrakizumab, risankizumab), IL-1 inhibitors (anakinra, canakinumab, rilonacept), T cell costimulation inhibitor (CTLA4-Ig/abatacept), B cell-depleting agents (rituximab, ocrelizumab, obinutuzumab), BLyS/BAFF inhibitors (belimumab,